Celgene to commercialize Juno CD19 program

By Melissa Fassbender contact

- Last updated on GMT

Juno currently has three CD19-directed product candidates in clinical development. (Image: iStock/royaltystockphoto)
Juno currently has three CD19-directed product candidates in clinical development. (Image: iStock/royaltystockphoto)

Related tags: Clinical trial

Celgene has exercised its option to develop and commercialize therapeutic antibody candidates that target CD19 - a protein found on cancerous B cells - in a deal with Juno therapeutics.

Celgene will pay Juno $50m for rights to its CD19 programme in markets outside North America and China. The companies will share global development expenses.

We believe CD19 holds great potential for B cell malignancies including areas of disease focus that correspond with our longstanding commitment to hematology​,” Celgene told us. “This is an important step in our long-term collaboration with Juno and we look forward to working on these programs​.”

Juno currently has three CD19-directed product candidates in clinical development, including JCAR015, JCAR017, and JCAR014. JCAR015 is in a Phase II trial, JCAR017 is in two separate Phase I trials, and JCAR014 is in a Phase I trial for three different indications.

As part of the deal, Juno will retain commercialization rights in North America and China. With rights outside of North America and China, Celgene will pay Juno a royalty at a percentage in the mid-teens on any future net sales of therapeutic products developed through the CD19 program.

Our CD19-directed portfolio of drug candidates has shown encouraging efficacy and manageable toxicity in trials to date across a range of B cell malignancies, and we are pleased that Celgene has decided to opt in to the CD19 program​,” said Hans Bishop, Juno’s President and Chief Executive Officer.

The long-term collaboration with Celgene is an important component of our plan to develop our engineered T cell platform rapidly and effectively for the benefit of patients around the world, and we are encouraged by the progress we are making together​.”

Juno is also currently developing multiple cell-based product candidates to treat various B-cell malignancies in addition to solid tumors. According to the company, several product candidates have shown “compelling clinical responses​” in clinical trials in refractory leukemia and lymphoma.

Related topics: Markets & Regulations, Phase I-II

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars